Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Urate oxidase (rasburicase) for treatment of severe tophaceous gout.

Literature DB >> 15673692

Urate oxidase (rasburicase) for treatment of severe tophaceous gout.

Bruno Vogt¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2005 PMID： 15673692 DOI： 10.1093/ndt/gfh629

Source DB: PubMed Journal: Nephrol Dial Transplant ISSN： 0931-0509 Impact factor: 5.992

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. Uricases as therapeutic agents to treat refractory gout: Current states and future directions.

Authors: Xiaolan Yang; Yonghua Yuan; Chang-Guo Zhan; Fei Liao
Journal: Drug Dev Res Date: 2011-12-29 Impact factor: 4.360

Review 2. New developments in clinically relevant mechanisms and treatment of hyperuricemia.

Authors: Susan J Lee; Robert A Terkeltaub
Journal: Curr Rheumatol Rep Date: 2006-06 Impact factor: 4.592

3. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.

Authors: Mattheus K Reinders; Eric N van Roon; Pieternella M Houtman; Jacobus R B J Brouwers; Tim L Th A Jansen
Journal: Clin Rheumatol Date: 2007-02-17 Impact factor: 2.980

4. Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy.

Authors: Yi Shi; Ting Wang; X Edward Zhou; Qiu-Feng Liu; Yi Jiang; H Eric Xu
Journal: Acta Pharmacol Sin Date: 2019-06-28 Impact factor: 6.150

5. Cloning, purification, and partial characterization of Bacillus subtilis urate oxidase expressed in Escherichia coli.

Authors: Pollyana Pfrimer; Lidia Maria Pepe de Moraes; Alexsandro Sobreira Galdino; Loise Pedrosa Salles; Viviane Castelo Branco Reis; Janice Lisboa De Marco; Maura Vianna Prates; Carlos Bloch; Fernando Araripe Gonçalves Torres
Journal: J Biomed Biotechnol Date: 2010-02-04

Urate oxidase (rasburicase) for treatment of severe tophaceous gout.

1. Uricases as therapeutic agents to treat refractory gout: Current states and future directions.

Review 2. New developments in clinically relevant mechanisms and treatment of hyperuricemia.

3. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.

4. Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy.

5. Cloning, purification, and partial characterization of Bacillus subtilis urate oxidase expressed in Escherichia coli.

Review 6. Management of hyperuricemia in gout: focus on febuxostat.

7. New advances in the treatment of gout: review of pegloticase.

Review 8. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.

Review 9. Uricase and other novel agents for the management of patients with treatment-failure gout.

Review 10. The emerging role of biotechnological drugs in the treatment of gout.